@nessy agree that it is good to see a pathway but the revenue appears to be for the provider not EIQ. " ..customers of Echo-Solv to obtain reimbursement of usage costs to a defined limit, the lesser of 60% of the cost of the underlying service or US 1040"

Still no clear picture of how EIQ will clip that ticket.

However it should be a big boost for uptake. Fingers crossed for FDA approval in early CY24